SparkMind (Nanjing) Technology Co., Ltd. (“SparkMind”) is a specialized contract research organization (CRO) dedicated to neuroscience and cardiovascular research. Founded in Nanjing in 2025, SparkMind provides integrated technology platforms that combine electrophysiology with advanced biological microscopy imaging for pharmaceutical companies and research institutions worldwide.
Our service model balances standardized experimental workflows with flexible, project-specific customization, supporting drug discovery, mechanism-of-action studies, and safety evaluation. Built on core platforms in electrophysiology and tissue/cell imaging, SparkMind has established a “cross-system, single-platform” research paradigm designed to improve experimental efficiency, data consistency, and cross-study comparability. Our core technical team is composed entirely of PhD-level scientists trained with a strong focus on data quality, traceability, and internationally aligned operational standards, supporting both drug development programs and high-impact scientific publications.
Team Background
SparkMind was founded by researchers with PhDs from Peking University. The team brings together experience in electrophysiology, functional imaging, clinical research, and industry, with a focus on neuroscience and cardiovascular drug development. Before the company was founded, team members explored the integration of electrophysiology and imaging, particularly high-throughput voltage-probe imaging for applications in these fields.
Compared with conventional single-cell patch-clamp recording, voltage-probe imaging can, under suitable experimental conditions, capture electrical activity from hundreds to thousands of cells in parallel. This provides a path toward higher throughput and larger datasets. Building on this research foundation, SparkMind established electrophysiology and biological microscopy platforms in the Nanjing Jiangbei New Area to support functional assessment, mechanism-of-action studies, and safety evaluation, with an emphasis on reproducibility and data traceability.
Core Technologies
SparkMind’s technology platform is built around patch-clamp electrophysiology and cellular functional imaging. Depending on the research objective, we select ion-channel, cell, tissue or organ-level models and assays. Voltage and calcium measurements, histopathology and multi-omics analysis provide complementary information to help researchers examine drug effects at functional, morphological and molecular levels.
In neuroscience, the platform covers acute brain slices, cultured neurons, dorsal root ganglion (DRG) sensory neurons and spinal cord slices. Patch-clamp recordings characterize neuronal excitability and synaptic function, while voltage and calcium imaging capture cellular and network activity. NaV1.7 ion-channel screening supports research on pain-related targets and candidate compounds.
In cardiac research, the platform offers routine hERG screening and testing under near-physiological temperature conditions. For primary cardiomyocytes, iPSC-derived cardiomyocytes and cardiac organoids, appropriate assays may be selected according to the model and study endpoint, including action potentials, calcium transients, voltage imaging, contractile function and electrical–calcium–contraction coupling. Isolated-heart perfusion supports studies of cardiac electrical activity and functional changes; in vitro evaluation services are also available for pulsed field ablation (PFA).
For projects requiring additional tissue- and molecular-level analysis, the histopathology platform supports sample preparation, staining and image analysis, while the multi-omics platform provides assays and bioinformatics analysis matched to the research question. Platform combinations, sample requirements and endpoints are defined for each project so findings from different levels can be interpreted together without treating different assays as interchangeable.
